Skip to main content
Click here to get access to our Free Course on Momentum Investing Strategy

Stock factor profile

DIVI'S LAB.

DIVISLAB · Healthcare · Pharmaceuticals & Biotechnology

Divi's Laboratories Ltd. is a holding company, which engages in the manufacture of active pharmaceutical ingredients, intermediates, and nutraceutical ingredients. The company is headquartered in Hyderabad, Telangana and currently employs 16,543 full-time employees. The Company’s products include Bupropion HCl, Capecitabine, Carbidopa, Diltiazem HCl, Dextromethorphan Base, Dextromethorphan HBr, Gabapentin, Iopamidol, Iohexol, Irbesartan, Lacosamide, Levetiracetam, Levodopa, Losartan, Nabumetone, Naproxen, Naproxen Sodium, Olmesartan Medoxomil, Pregabalin, Ticagrelor, Triprolidine HCl, Valacyclovir HCl, Valsartan, Venlafaxine HCl and Vigabatrin. The Company’s subsidiaries include Divi’s Laboratories USA, Inc., (Divi’s USA) and Divi’s Laboratories Europe AG (Divi’s Europe).

DIVI'S LAB. reported revenue of ₹3,676 crore for Sep 2026, up 35.4% from a year earlier. Net profit was ₹1,127 crore (up 63.6% year on year). Return on equity was 15.3% in Mar 2026. Promoter holding was 51.88% in Sep 2026, down 0.01 points over 8 quarters.

Last price₹11059.50
1 day+0.1%
1 month+21.71%
Model ratingLocked
Data as of19 Nov 2026

Performance

Price history

Equity review factors

Factor profile

Factor scores are part of the Wright portfolio review.

Run your free portfolio review

Fundamental snapshot

Fundamentals at a glance

Market cap₹175621 cr
P/E ratio—
Factor betaLocked
VolatilityLocked
Model scoreLocked
Screen passLocked

Reported results

Quarterly (₹ crore)

Sep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue36763080283126042715241025852319
Net profit1127902751583689545662589
Net margin %30.729.326.522.425.422.625.625.4
EPS (₹)42.4533.9828.2921.9625.9520.5324.9422.19

Reported results

Annual (₹ crore)

FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019
Revenue105609360784577688960696953944946
Net profit25682191160018232960198413771353
Net margin %24.323.420.423.533.028.525.527.3
EPS (₹)96.7382.5360.2768.69111.5274.7551.8550.96

Ratios · Mar 2026

Returns, leverage and growth

Return on equity15.3%
Return on capital19.0%
EBITDA margin35.0%
Net margin23.2%
Debt to equity0.00
Interest cover148.3x
Revenue growth, 3y CAGR10.9%
Revenue growth, 5y CAGR9.5%
Profit growth, 3y CAGR12.1%
Profit growth, 5y CAGR5.3%
Mar 2026Mar 2025Mar 2024Mar 2023
ROE %15.314.611.814.3
EBITDA margin %35.034.231.133.4
Net margin %23.222.619.622.5

Ownership

Shareholding pattern (%)

Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026Change
Promoter51.8951.8951.8951.8951.8851.8851.8851.88-0.01
FII17.9918.0119.7419.3920.0820.2920.220.382.39
DII20.5420.7119.0519.7619.2819.2219.3819.17-1.37
Public9.589.399.328.968.768.68.548.58-1.0

Mutual fund holdings · Oct 2026

440 schemes hold this stock

310 the month before.

  • ICICI Prudential Nifty Pharma ETF12.29% of NAV
  • Nippon India Nifty Pharma ETF12.28% of NAV
  • ICICI Prudential Nifty Pharma Index Fund12.28% of NAV
  • PGIM INDIA HEALTHCARE FUND11.08% of NAV
  • ADITYA BIRLA SUN LIFE NIFTY HEALTHCARE ETF10.78% of NAV
  • DSP Nifty Healthcare Index Fund10.78% of NAV
  • Axis NIFTY Healthcare ETF10.78% of NAV
  • ICICI Prudential Nifty Healthcare ETF10.78% of NAV

See what mutual funds are buying

Corporate actions

Recent dividends, bonuses and splits

  • 25 Jul 2025 · Final Dividend - Rs. 30
  • 02 Aug 2024 · Dividend - Rs. 30
  • 11 Aug 2023 · Final Dividend - Rs. 30
  • 11 Aug 2022 · Dividend - Rs. 30
  • 17 Aug 2021 · Final Dividend - Rs. 20
  • 25 Feb 2020 · Interim Dividend - Rs. 16

Financials are as reported by the company (consolidated), in ₹ crore. Source: FinEdge exchange filings feed. Figures can differ from other sites because of one-off items and restatements.

Research data on this page is provided under Wright Research's SEBI Research Analyst registration. The Terms & Conditions of our Research Analyst services apply.